Article

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general population

2024-02-29

Abstract excerpt

<h4>Background</h4> Treatment with monoclonal antibodies against amyloid-β slowed cognitive decline in recent randomized clinical trials in patients with mild cognitive impairment (MCI) and early dementia due to Alzheimer’s disease (AD). However, stringent trial eligibility criteria may affect generalizability of these findings to clinical practice. <h4>Methods</h4> We extracted eligibility criteria for trials of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 529979d7-0eb6-505a-984b-5920a18ce876
DOI: 10.1101/2024.02.29.24303553

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationDOI 10.1101/2024.02.29.24303553Read

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?Semantic proximity Read

Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes.Semantic proximity Read

Are Pre-frail and Frail Amyloid Positive Individuals Eligible to Lecanemab? A cross-sectional analysis from the Cogfrail Real-World CohortSemantic proximity Read

Precision Medicine Treatment of Alzheimer’s Disease: Successful Randomized Controlled TrialSemantic proximity Read

Reducing ARIA risk in Alzheimer's disease: Real-world impact of APOE genotype-guided slow titration with aducanumab and lecanemab.Semantic proximity Read

Adjudicating mild cognitive impairment due to Alzheimer’s disease as a novel endpoint event in the TOMMORROW prevention clinical trialSemantic proximity Read

The science does not yet support regulatory approval of amyloid‐targeting therapies for Alzheimer's disease based solely on biomarker evidenceSemantic proximity Read

Use of preclinical Alzheimer’s disease trajectories for clinical trial designSemantic proximity Read

An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.Semantic proximity Read

Precision Medicine Treatment of Alzheimer’s Disease: Successful Randomized Controlled TrialSemantic proximity Read

Precision Medicine Approach to Alzheimer’s Disease: Successful Proof-of-Concept TrialSemantic proximity Read

A Machine Learning Approach to Predict Cognitive Decline in Alzheimer’s Disease Clinical TrialsSemantic proximity Read